Abstract
Keywords
Genotyping Adverse drug reactions CYP2C19 Pakistanis Single nucleotide polymorphisms Ethnic groups
Introduction
Adverse drug reactions (ADRs) and failure to therapeutics represent a major health problem and constitute a big challenge for drug development. The enzymatic transformation of therapeutically important compounds into active, inactive or more soluble forms is catabolized by cytochrome P450 system (1). CYP1, 2, and 3 are involved in the metabolism of more than 75% clinically used drugs; CYP2C19 being a part of CYP2 family is mainly involved in the metabolism of Proton Pump Inhibitors (PPI) and antiepileptics. Omeprazole the most widely sold PPI is included in the WHO Essential list of medicines. Apart from PPI some antiplatelet drugs such as clopidogrel, antiepileptic (mephenytoin), and antimalarial (proguanil) are also metabolized by CYP2C19.
CYP2C19 has more than twenty variant alleles but most important *2, *3, *4, *5, *6, *7, and *8 are associated with reduced enzyme function (2). CYP2C19*1 represents the wild type allele and its homozygotes are known as extensive metabolizers. CYP2C19*2 is the most important variant formed due to the splice site defect in exon 5 (single base change G > A) of the gene and is marked for loss of function allele. It accounts for more than 90% of CYP2C19 poor metabolizers and individual with its homozygous defective alleles are termed as PM (3). Apart from loss of function alleles, a promoter variant CYP2C19*17 of CYP2C19 leads to increased activity of the gene and is classified as ultra-rapid metabolizer. Individuals with CYP2C19*17 both heterozygous and homozygous form are rapid metabolizers (4).
About 10-20% of patients treated with PPIs are nonresponders to the treatment. Frequency of CYP2C19 poor and rapid metabolizers varies worldwide; Asians (12-23%) and East Asian (14-39%) are reported to have highest occurrence of poor metabolizers (5, 6). Also, Africans (24%) and Europeans (22%) have higher frequency of rapid metabolizers (http://asia.ensembl.org). Diverse pharmacogenetic properties of individuals play an important role in failure to the treatment; therefore, it is imperative to know the individual’s genotype before starting any treatment.
Pakistan consists of a population comprising of various ethnic groups residing in different regions of the country each claiming diverse ethnic origin. Therefore, it is very important to know the CYP450 genotypic composition of these populations in order to avoid adverse drug reactions in these individuals. The present study was planned to explore various Pakistani ethnic groups for prevalence of two most common allelic variants CYP2C19*2 and CYP2C19*17 involved in the poor or rapid metabolism of some of the important drugs.
Experimental
Study population
The study population included one thousand and twenty-eight (n = 1028) unrelated healthy Pakistani subjects. These samples were collected from nine ethnic groups including Brusho (n = 28), Hazara (n = 102), Kalash (n = 64), Pathan (n = 170), Punjabi (n = 218), Saraiki (n = 59), Brahui (n = 118), Parsi (n = 90), and Sindhi (n = 179). A written informed consent was obtained from all subjects before participation in the study. Blood samples (5 mL in tubes containing EDTA) were collected from the subjects and DNA was extracted from peripheral blood leukocytes by phenol chloroform method (7). The study was approved by the Ethical Committee of Institute of Biomedical and Genetic Engineering (IBGE), Islamabad and the Institutional Review Board (IRB) of Quaid-i-Azam University, Islamabad.
Genotyping
CYP2C19 alleles CYP2C19*2 (c.G681A; rs4244285) and CYP2C19*17 (c.C806T; rs12248560) were genotyped by ASA-PCR and the primer sequences are given in supplementary data (Table S1A and S1B). The amplified products were detected on 2% agarose gels for genotyping. Each PCR was carried out in 20 µL volume using 1.5 mM MgCl2, 50 mM KCl, 200 µM dNTPs, 10 mM Tris-HCl, 0.5 µM of each forward and reverse primer, 1 units of Taq DNA polymerase (Fermentas), and 100 ng of DNA sample. PCR amplification of CYP2C19*2 region was carried out by initial denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 62 °C for the amplification of “A” allele-specific DNA fragment and 60 °C for “G” allele-specific DNA fragment for 40 sec, extension at 72 °C for 1 min followed by final extension at 72 °C for 5 min. Thermal profile for the amplification of CYP2C19*17 was similar to CYP2C19*2 amplification except annealing at 58 °C for both alleles. The phenotypes were inferred from the genotypes.
Results
Our findings (Table 1) demonstrated the genotyping results for nine ethnic groups of Pakistan. The individuals were classified as extensive metabolizers (EM), intermediate metabolizers (IM), ultrarapid metabolizers (UM), and poor metabolizers (PM) depending on their genotype: EM had both functional alleles (*1/*1), IM had one functional and one loss of functional allele or one nonfunctional allele and one increased activity allele (*1/*2, *2/*17), UM carried both increased activity allele or one normal and one increased activity allele (*17/*17, *1/*17) and PM were those with both nonfunctional alleles (*2/*2) (8).
Among all the groups studied, CYP2C19*1 allele was predominant with allele frequency varying from 36% to 70% (Table 1 and Figure 1). However, the genotype frequency for extensive metabolizers (*1/*1) varied from 20% to 46% with an average of 30% for all ethnic groups. The overall frequency of PM allele for all groups was 29% with Burusho showing the lowest (10%) and the Saraikis showing the highest frequency (40%). The PM genotype (*2/*2) was highest in Saraikis (20%) whereas, in other ethnic groups it varied from 0 to 9%. Burusho and Parsi did not show any PM genotype. UM allele frequency averaged to 24% with highest in Parsi and lowest in Saraiki ethnic groups. At genotype level, the overall frequency of UM was 18% and it ranged from 10% to 39%. The frequency of IM was quite high about 46% for all populations with Brahui having the highest frequency (60%). At population level, IM genotype frequency was higher for most of the populations except Burusho and Parsi; Burusho had higher EM genotype and Parsi had UM as highest genotype (Figure 2). Our observation for the allele frequencies of *2 and *17 in Pakistani population was similar to that reported previously. Over all the percentage of predicted PM allele was present in 29.0% individuals compared to UM allele which was 23.70%.
Discussion
Advancement in the field of Pharmacology has tremendous potential for management of various ailments. At the same time adverse drug reaction or drug-drug interaction can lead to various complications. CYP450 system plays an important role in the metabolism of pharmacologically active compounds; CYP2C19 accounts for bio-transformations of most of the PPI and antiepileptics.
Globally the pattern of transformations through CYP2C19 varies; Pakistan is situated on the southern coastal route from Africa to Australia (9). It has at least 18 different ethnic groups who speak >60 languages, mostly Indo-European languages but there are also some language isolates including Burushaski, Brahui, and Balti (9). Among the nine populations studied Burusho, Kalash, Hazara, and Pathan are found in Khyber Pukhtoonkhwa (KPK) province in the northern region of the country. Punjabi and Saraiki are in Punjab, Brahui in Baluchistan, and Parsi and Sindhi in Sindh province, in the south of Pakistan. Kalash, Burusho, and Pathan claim Greek origin whereas Hazara look like Mongols. Punjabi and Sindhi populations have admixture of other ethnic groups however Parsi have Iranian origin. The Brahuis have more complex origin, that is Indo-Iranian from Central Asia to East (9-11). The Saraikis depict historic pre-Aryan people of a Semite origin (12). Most of the studies have supported the genetic diversity among Pakistani populations and genetic clusters lie close to European populations (13, 14).
Predicted phenotypes for various Pakistani Ethnic Groups (n = 1028)
| North Populations | South Populations | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENOTYPE | Predicted | Burushu | Hazara | Kalash | Pathan | Punjabi | Saraiki | Buruhi | Parsi | Sindhi | |
| Phenotype | (n = 28) | (n = 102) | (n = 64) | (n = 170) | (n = 218) | (n = 59) | (n = 118) | (n = 90) | (n = 179) | Total | |
| *1/*1 | EM | 13 (46%) | 28 (27%) | 18 (28%) | 54 (32%) | 60 (28.0%) | 19 (30%) | 24 (20%) | 27 (30%) | 63 (35.20%) | 306 (29.80%) |
| *1/*17 | UM | 11 (39%) | 30 (29%) | 5 (8%) | 22 (13%) | 34 (16%) | 5 (10%) | 14 (12%) | 26 (29%) | 19 (10.60%) | 166 (16.10%) |
| *2/*17 | IM | 1 (4%) | 22 (22%) | 29 (45%) | 48 (28%) | 53 (24%) | 6 (10%) | 49 (41%) | 24 (26%) | 42 (23.50%) | 274 (26.70%) |
| *1/*2 | IM | 3 (11.0%) | 19 (19%) | 7 (11%) | 31 (18.0%) | 49 (22%) | 19 (30%) | 22 (19%) | 5 (6%) | 39 (21.80%) | 194 (18.90%) |
| *2/*2 | PM | 0 (0%) | 0 (0%) | 3 (5%) | 12 (7%) | 16 (7%) | 10 (20%) | 7 (6%) | 0 (0%) | 16 (8.90%) | 64 (6.20%) |
| *17/*17 | UM | 0 (0%) | 3 (3%) | 2 (3%) | 3 (2%) | 6 (3%) | 0 (0%) | 2 (2%) | 8 (9%) | 0 (0%) | 24 (2.30%) |
| ALLELE | |||||||||||
| *1 | EM | 40 (70%) | 105 (50%) | 48(37.5%) | 161 (50%) | 203 (50%) | 62 (50%) | 84 (35.6%) | 85 (47%) | 184 (50%) | 972 (47.30%) |
| *2 | PM | 4 (10%) | 41 (20%) | 42(32.8%) | 103 (30%) | 134 (30%) | 45 (40%) | 85 (36%) | 29 (16%) | 113 (30%) | 596 (29.00%) |
| *17 | UM | 12 (20%) | 58 (30%) | 38(29.7%) | 76 (20%) | 99 (20%) | 11 (10%) | 67 (28.4%) | 66 (37%) | 61 (20%) | 488 (23.70%) |
CYP2C19 polymorphism study was planned because of its importance in many cardiovascular, antiepileptic drugs and due to high prevalence of poor metabolizers in European and Asian populations. This type of study is important to avoid adverse drug reactions (ADRs) and extra financial burden on patients. CYP2C19 enzyme is responsible for inter-individuals and inter-ethnic differences within ethnic groups and between other ethnic groups in the world. The CYP2C19*2 allelic frequency in Pakistan is similar to other Asian countries namely Orientals, Thai, Korean, Japanese, and North Indians (15-19). Overall Asians represent high frequency of *2 allele compared to other countries (20). Allelic frequency of CYP2C19*17 in Pakistan is 23.7% which is similar to most of the Europeans including Danish, Norway, and Germany (21, 22). Among Asians the frequency is mostly lower except Saudi Arabia where it is 25.7% (23). From the world-wide distribution of CYP2C19*2 allele frequency it is obvious that it has relatively higher frequency compared to other variants showing this detrimental mutation is relatively older and occurred before the Black, Oriental and Caucasian racial groups split” (24, 25). Population frequency shown in this study will be helpful to recommend CYP2C19 (*2 and *17) typing as a pre-treatment test to monitor drug dosage (personalized medicine) to avoid ADRs as a personalized medicine approach. The study results might allow us in future to detect genetic variations in drug-metabolizing enzymes which are useful for clinicians to suggest right dosage and efficacy of drugs metabolized by this polymorphic enzyme to avoid adverse drugs reactions.
Conclusion
CYP450 genotyping helps to identify those individuals who are at the risk of ADRs with routine doses of some commonly used drugs. Thus, clinicians can prescribe the right drug and acceptable dosage for the patients which in turn can prevent discomfort of taking unnecessary medicines and extra financial burden on the patients.
Acknowledgements
References
-
1.
Guengerich FP. Cytochrome P450 and Chemical Toxicology. Chem. Res. Toxicol. 2008;21:70-83. [PubMed ID: 18052394].
-
2.
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306:2704-14. [PubMed ID: 22203539].
-
3.
Helsby NA, Burns KE. Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19. Front. Genet. 2012;3:206. [PubMed ID: 23087703].
-
4.
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 2011;90:328-32. [PubMed ID: 21716271].
-
5.
Mathijssen RHJ, Van Schaik RHN. Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment. Eur. J. Cancer. 2006;42:141-8. [PubMed ID: 16325399].
-
6.
Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, Satyanarayanamoorthy K, Peter A, Rajagopal K. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam. Clin. Pharmacol. 2005;19:101-5. [PubMed ID: 15660966].
-
7.
Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. 2nd ed. New York; 1989. p. 16-23.
-
8.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, AR Shuldiner. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 Update. Clin. Pharmacol. Ther. 2013;94:317-23. [PubMed ID: 23698643].
-
9.
Qamar R, Ayub Q, Mohyuddin A, Helgason A, Mazhar K, Mansoor A, Zerjal T, Tyler-Smith C, Mehdi SQ. Y-chromosomal DNA variation in Pakistan. Am. J. Hum. Genet. 2002;70:1107-24. [PubMed ID: 11898125].
-
10.
Grimes B. . 13th ed. Taxas, USA: Summer Inst. Linguist. Inc; 1992 Ethnologue: Languages of the World.
-
11.
Mehdi SQ, Qamar R, Ayub Q, Kaliq S, Mansoor A, Ismail M, Hammer MF, Underhill PA, Cavalli-Sforza LL. The origins of Pakistani populations: evidence from Y chromosome markers. In: Papiha SS, Deka R, Chakraborty R, editors. Genomic diversity: applications in human population genetics. New York: Kluwer Academic/Plenum Publishers; 1999. p. 83-90.
-
12.
Shackle C. Siraiki: A Language Movement in Pakistan. Mod. Asian Stud. 1977;11:379-403.
-
13.
Ayub Q, Mansoor A, Ismail M, Khaliq S, Mohyuddin A, Hameed A, Mazhar K, Rehman S, Siddiqi S, Papaioannou M, Piazza A, Cavalli-Sforza L, Mehdi SQ. Reconstruction of human evolutionary tree using polymorphic autosomal microsatellites. Am. J. Phys. Anthropol. 2003;122:259-68. [PubMed ID: 14533184].
-
14.
Mansoor A, Mazhar K, Khaliq S, Hameed A, Rehman S, Siddiqi S, Papaioannou M, Cavalli-Sforza LL, Mehdi SQ, Ayub Q. Investigation of the Greek ancestry of populations from northern Pakistan. Hum. Genet. 2004;114:484-90. [PubMed ID: 14986106].
-
15.
Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br. J. Clin. Pharmacol. 2003;56:331-3. [PubMed ID: 12919183].
-
16.
Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Na-Bangchang K, Tawalee A, Krikreangsak N, Cykleng U, Tassaneeyakul W. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 2006;21:286-90. [PubMed ID: 16946555].
-
17.
Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J. Clin. Pharm. Ther. 2010;35:697-703. [PubMed ID: 21054462].
-
18.
Sugimoto K, Lino T, Yamazalci H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br. J. Clin. Pharmacol. 2008;65:437-9. [PubMed ID: 18241287].
-
19.
Yadav SS, Ruwali M, Shah PP, Mathur N, Singh RL, Pant MC, Parmar D. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response. Mutat. Res. 2008;644:31-7. [PubMed ID: 18644391].
-
20.
Tabari RG, Marjani A, Ataby OA, Mansourian AR, Samai NM. Genetic polymorphism of cytochrome p450 (2C19) enzyme in Iranian Turkman ethnic group. Oman Med. J. 2013;28:237-44. [PubMed ID: 23904915].
-
21.
Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Hailing J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, Ingelman-Sundberg M. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 2010;66:1199-205. [PubMed ID: 20665013].
-
22.
Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9:1251-9. [PubMed ID: 18781853].
-
23.
Saeed LH, Mayet AY. Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int. J. Med. Sci. 2013;10:1497-502. [PubMed ID: 24046523].
-
24.
Negin Z, Nader T, Mahmood H, Moghaddam salek A, Iraj M. Allele frequency of CYP2C19 gene polymorphisms in a healthy Iranian population. Iran. J. Pharmacol. Ther. 2006;4:124-8.
-
25.
Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 2004;50:195-200. [PubMed ID: 15177309].